Mar 04, 2019 · Nightstar has several gene therapy assets, but Biogen called one, the “NSR-REP1,” the most important of the bunch. NSR-REP1 is a possible treatment for a rare disorder of the retina called...
Isarna Therapeutics develops TGF-β inhibitors to effectively treat ophthalmic and ... KalVista Pharmaceuticals. Business Area(s): ... Nightstar Therapeutics.
Nightstar Therapeutics (formerly known as NightstaRx) is a clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases.
Aktienempfehlung vom 17.12.18: Die Experten der Barclays Capital bewerten die Aktie von Nightstar Therapeutics mit overweight.
Jan 05, 2021 · NightStar Therapeutics (NSR-REP1 for choroideremia) Orchard Therapeutics (OTL-103 for the Treatment of Wiskott-Aldrich Syndrome) Poseida Therapeutics (P-BCMA-101 for multiple myeloma) Rocket Pharma (RP-L102 for Fanconi Anemia) SanBio (SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury)
Nightstar Therapeutics PLC. NITE 25.41 0.01 (0.04%). PRIVATE Updated Jun 6, 2019 8:00 PM
Jan 06, 2021 · Nightstar Therapeutics – NSR-REP1 for Choroideremia (progressive vision loss) (06/14/18) Novartis – Kymriah® for patients with relapsed or refractory (r/r) follicular lymphoma (04/22/20) Orca Bio – Orca-T, an experimental allogeneic cell therapy for patients with blood cancers who are eligible for a hematopoietic stem cell transplant (10/15/20).
Jan 05, 2021 · Prior to joining Nightstar Therapeutics, he was the Vice President of Johnson & Johnson’s Vision Care Franchise where he led global marketing, new product and licensing activities. Before ...
Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences November 05, 2020 Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates